Therefore, we find it necessary to understand PD-L1 expression in the context of treatment and response, and the combination of PD-L1 antibody with CD73 antibody may be the preferable approach to beat the current limitation due to the complicated immune suppressive pathways in the tumour microenvironment. The gene discussed is NT5E; the disease is neoplasm.